Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
about
Vaccinia-based influenza vaccine overcomes previously induced immunodominance hierarchy for heterosubtypic protection.Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70(359-610)) fusion protein against influenza virus infection in mice.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Universal influenza vaccines: Shifting to better vaccines.Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic.Influenza A viruses: why focusing on M2e-based universal vaccines.Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.Subviral particle as vaccine and vaccine platform.Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice.Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing proteinRecombinant M2e protein-based ELISA: a novel and inexpensive approach for differentiating avian influenza infected chickens from vaccinated ones.A novel M2e based flu vaccine formulation for dogs.A candidate dual vaccine against influenza and noroviruses.Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.Characterization of the M2e antibody response following highly pathogenic H5N1 avian influenza virus infection and reliability of M2e ELISA for identifying infected among vaccinated chickens.Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.Production of H5N1 Influenza Virus Matrix Protein 2 Ectodomain Protein Bodies in Tobacco Plants and in Insect Cells as a Candidate Universal Influenza Vaccine.Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System.A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Developments of subunit and VLP vaccines against influenza A virus.Recombinant influenza vaccines.Hepatitis B core-based virus-like particles to present heterologous epitopes.Recent outbreaks of highly pathogenic avian influenza viruses in South Korea.SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure.Chimaeric VP2 proteins from infectious bursal disease virus containing the N-terminal M2e of H9 subtype avian influenza virus induce neutralizing antibody responses to both viruses.Adjuvant formulations for virus-like particle (VLP) based vaccines.Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection.Monomeric M2e antigen in VesiVax® liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e.Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine.Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.Escherichia coli-derived virus-like particles in vaccine development.
P2860
Q30362529-2D7B9279-C558-49D4-B22A-245BE6549ACEQ30366089-B87DE724-6A7B-4DDE-AE4F-EB5E31EE66BCQ30375991-81F891CD-F430-4B27-B3F9-4B290B715035Q30386388-29B2AF60-DD30-4A5F-A175-C4E2AAC1A874Q30392924-75D1B451-77C1-4F94-BA5E-22B52A1D1B84Q30396318-AA12F7C2-FC64-4C99-9DDF-F9D7CBA807FEQ30398228-068A6804-CD34-4D0D-B244-574454B53C37Q30400230-D623A0CE-C25F-4578-9A10-0AAEE1715B6AQ33812653-F3837B70-A734-477C-80A0-4508036EA5AFQ34105207-A946330B-B29F-4246-B633-67197869D71CQ34430020-6C478E5E-EBE3-4CC0-92F1-82A214F69778Q34437654-A4CE97A1-C147-4C47-A0E5-9B36CDFAAA4BQ34599505-BD7EE204-DE7B-4F6D-B682-65FF456A01BEQ35009732-8D185ED6-D91F-430D-B488-C39C7F28113BQ35301295-71F50774-0220-467B-95E5-984831E225C1Q35606494-254D12A0-910C-4365-AAD8-2F5D36048A73Q35615141-8D0A72FC-F752-44D9-B601-A05ECFD5519AQ36267431-E14EA42C-1E71-4514-BEBE-85693C89FCACQ36352851-676679B9-A77D-47EF-93E2-DC334C0E67A0Q36849935-741F36B4-F103-43DA-B810-EC23D8784B8FQ37547653-4908A330-BDD4-4C6F-BDC6-58E958020472Q37645689-CFBBD2AD-DB69-445F-9FBD-EDD583A9C350Q37951525-DFC44275-52EB-4310-A34D-F457ED89F12CQ38017605-A1C84DF2-30A6-49A6-9399-93FFD03ED05FQ38076422-43B787CF-2AC6-4E7D-BE49-A78EEEE13B32Q38081969-6A8F5F08-1456-439C-8E25-FD60637F9972Q38647070-3C3EA95D-D1FF-4113-A2B7-B27B769B46F1Q39118758-974AB7DB-3E5F-4F6A-B152-B75C95A8115CQ39162472-370480FD-16E5-41A2-9DD9-604E476A45C0Q40093469-9587897B-F386-41B0-983C-E36EF11D0866Q41031005-6D1A80C4-8A16-475C-A3DC-0D8D7E8073FFQ42059898-972A8334-C420-4100-B3B4-7822B6ABBF1CQ44504298-6EA3BDF3-33F7-4F4F-9C5E-2B40C565214FQ45157613-612E9AE3-4081-4266-A1C9-35CA2B89A4FFQ45358078-D8F834B7-D67E-498F-A404-8CD934406C38Q45369861-C475C145-DB6F-4AEF-AD20-474323C0D154Q47132009-D40400A0-5B34-4364-A1EF-C01827810A8B
P2860
Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Universal influenza A M2e-HBc ...... -existing anti-HBc antibodies.
@en
Universal influenza A M2e-HBc ...... -existing anti-HBc antibodies.
@nl
type
label
Universal influenza A M2e-HBc ...... -existing anti-HBc antibodies.
@en
Universal influenza A M2e-HBc ...... -existing anti-HBc antibodies.
@nl
prefLabel
Universal influenza A M2e-HBc ...... -existing anti-HBc antibodies.
@en
Universal influenza A M2e-HBc ...... -existing anti-HBc antibodies.
@nl
P2093
P1433
P1476
Universal influenza A M2e-HBc ...... -existing anti-HBc antibodies.
@en
P2093
Anouk Smet
Ashley Birkett
Marina De Filette
Michael Schotsaert
Patricia Londoño-Arcila
Walter Fiers
Wouter Martens
Xavier Saelens
P304
P356
10.1016/J.VACCINE.2008.09.038
P407
P577
2008-12-01T00:00:00Z